BridgeBio Pharma (BBIO) Gross Profit (2020 - 2026)

BridgeBio Pharma's Gross Profit history runs 7 years deep, the most recent figure standing at $184.6 million for Q1 2026.

• In Q1 2026, Gross Profit rose 61.92% year-over-year to $184.6 million; the TTM figure through Mar 2026 stood at $551.7 million (up 354.09% YoY), while the FY2025 annual figure was $481.1 million, up 120.67% from the prior year.
• Gross Profit came in at $184.6 million for Q1 2026 at BridgeBio Pharma, up from $146.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $210.5 million in Q1 2024 to a low of -$401000.0 in Q3 2022.
• A 5-year average of $60.3 million and a median of $3.6 million in 2023 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit slumped 145.06% in 2022 and jumped 17816.77% in 2024, its largest moves.
• BridgeBio Pharma's Gross Profit stood at $1.2 million in 2022, then retreated by 6.21% to $1.1 million in 2023, then surged by 231.12% to $3.8 million in 2024, then soared by 3746.0% to $146.1 million in 2025, then climbed by 26.36% to $184.6 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $184.6 million, $146.1 million, and $114.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison